Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00296803 · ClinicalTrials.gov registry record · Phase 4
PROCLAIM: Study Examining Effects of Clopidogrel Compared to Placebo on Inflammation in Subjects With Metabolic Syndrome
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 216
- Enrollment target
NCT00296803 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 216 participants.
The verdict
NCT00296803, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 216 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effects of clopidogrel compared to placebo on markers of inflammation in subjects with metabolic syndrome who are receiving background therapy including low dose aspirin.
Interventions
- DRUG clopidogrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00296803
The ClinicalTrials.gov registry entry for NCT00296803 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which clopidogrel is the first listed.
NCT00296803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00296803 about?
NCT00296803 is a clinical study titled "PROCLAIM: Study Examining Effects of Clopidogrel Compared to Placebo on Inflammation in Subjects With Metabolic Syndrome". The purpose of this study is to examine the effects of clopidogrel compared to placebo on markers of inflammation in subjects with metabolic syndrome who are receiving background therapy including low dose aspirin.
What is the current status of trial NCT00296803?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 216 participants. The study started on 2005-11. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00296803?
The interventions under investigation include: clopidogrel (DRUG).
Who is sponsoring clinical trial NCT00296803?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.